Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $18.8750.

Several research firms have recently weighed in on LXEO. Chardan Capital restated a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 15th.

Insider Activity at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock in a transaction on Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the sale, the chief executive officer owned 340,106 shares of the company’s stock, valued at $1,935,203.14. The trade was a 13.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 59,644 shares of company stock valued at $336,462 over the last three months. Insiders own 5.30% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

Several large investors have recently modified their holdings of LXEO. RA Capital Management L.P. bought a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $49,650,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $47,299,000. Balyasny Asset Management L.P. bought a new stake in shares of Lexeo Therapeutics in the second quarter worth $16,117,000. Avoro Capital Advisors LLC bought a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $32,769,000. Finally, State Street Corp grew its holdings in Lexeo Therapeutics by 485.1% during the fourth quarter. State Street Corp now owns 3,187,722 shares of the company’s stock valued at $31,654,000 after purchasing an additional 2,642,877 shares during the period. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

LXEO stock opened at $5.14 on Wednesday. Lexeo Therapeutics has a 1-year low of $2.51 and a 1-year high of $10.99. The business has a fifty day moving average price of $5.82 and a 200-day moving average price of $7.45. The stock has a market capitalization of $403.60 million, a P/E ratio of -3.54 and a beta of 1.52.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. As a group, analysts anticipate that Lexeo Therapeutics will post -1.19 earnings per share for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.